Skip to Content


Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Prescription Drug Marketing Act of 1987; Administrative Procedures, Policies, and Requirements

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.


Fax written comments on the collection of information by March 30, 2015.

Start Printed Page 10698


To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to All comments should be identified with the OMB control number 0910-0435. Also include the FDA docket number found in brackets in the heading of this document.

Start Further Info


FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002,

End Further Info End Preamble Start Supplemental Information


In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Prescription Drug Marketing Act of 1987; Administrative Procedures, Policies, and Requirements—21 CFR Part 203—(OMB Control No. 0910-0435)—(Extension)

FDA is requesting OMB approval under the PRA (44 U.S.C. 3501-3520) for the reporting and recordkeeping requirements contained in the regulations implementing the Prescription Drug Marketing Act of 1987 (PDMA). PDMA was intended to ensure that drug products purchased by consumers are safe and effective and to avoid an unacceptable risk that counterfeit, adulterated, misbranded, subpotent, or expired drugs are sold.

PDMA was enacted by Congress because there were insufficient safeguards in the drug distribution system to prevent the introduction and retail sale of substandard, ineffective, or counterfeit drugs, and that a wholesale drug diversion submarket had developed that prevented effective control over the true sources of drugs.

Congress found that large amounts of drugs had been reimported into the United States as U.S. goods returned causing a health and safety risk to U.S. consumers because the drugs may become subpotent or adulterated during foreign handling and shipping. Congress also found that a ready market for prescription drug reimports had been the catalyst for a continuing series of frauds against U.S. manufacturers and had provided the cover for the importation of foreign counterfeit drugs.

Congress also determined that the system of providing drug samples to physicians through manufacturers' representatives had resulted in the sale to consumers of misbranded, expired, and adulterated pharmaceuticals.

The bulk resale of below-wholesale priced prescription drugs by health care entities for ultimate sale at retail also helped to fuel the diversion market and was an unfair form of competition to wholesalers and retailers who had to pay otherwise prevailing market prices.

FDA is requesting OMB approval for the following existing reporting and recordkeeping requirements:

Table 1—Reporting Requirements

21 CFR sectionRequirement
203.11Applications for re-importation to provide emergency medical care.
203.30(a)(1) and (b)Drug sample requests (drug samples distributed by mail or common carrier).
203.30(a)(3), (a)(4), and (c)Drug sample receipts (receipts for drug samples distributed by mail or common carrier).
203.31(a)(1) and (b)Drug sample requests (drug samples distributed by means other than the mail or a common carrier).
203.31(a)(3), (a)(4), and (c)Drug sample receipts (drug samples distributed by means other than the mail or a common carrier).
203.37(a)Investigation of falsification of drug sample records.
203.37(b)Investigation of a significant loss or known theft of drug samples.
203.37(c)Notification that a representative has been convicted of certain offenses involving drug samples.
203.37(d)Notification of the individual responsible for responding to a request for information about drug samples.
203.39(g)Preparation by a charitable institution of a reconciliation report for donated drug samples.

Table 2—Recordkeeping Requirements

21 CFR sectionRequirement
203.23(a) and (b)Credit memo for returned drugs.
203.23(c)Documentation of proper storage, handling, and shipping conditions for returned drugs.
203.30(a)(2) and 203.31(a)(2)Verification that a practitioner requesting a drug sample is licensed or authorized by the appropriate State authority to prescribe the product.
203.31(d)(1) and (d)(2)Contents of the inventory record and reconciliation report required for drug samples distributed by representatives.
203.31(d)(4)Investigation of apparent discrepancies and significant losses revealed through the reconciliation report.
203.31(e)Lists of manufacturers' and distributors' representatives.
203.34Written policies and procedures describing administrative systems.
203.37(a)Report of investigation of falsification of drug sample records.
203.37(b)Report of investigation of significant loss or known theft of drug samples.
203.38(b)Records of drug sample distribution identifying lot or control numbers of samples distributed. (The information collection in 21 CFR 203.38(b) is already approved under OMB control number 0910-0139).
203.39(d)Records of drug samples destroyed or returned by a charitable institution.
203.39(e)Record of drug samples donated to a charitable institution.
203.39(f)Records of donation and distribution or other disposition of donated drug samples.
203.39(g)Inventory and reconciliation of drug samples donated to charitable institutions.
203.50(a)Drug origin statement.
203.50(b)Retention of drug origin statement for 3 years.
203.50(d)List of authorized distributors of record.
Start Printed Page 10699

The reporting and recordkeeping requirements are intended to help achieve the following goals: (1) To ban the reimportation of prescription drugs produced in the United States, except when reimported by the manufacturer or under FDA authorization for emergency medical care; (2) to ban the sale, purchase, or trade, or the offer to sell, purchase, or trade, of any prescription drug sample; (3) to limit the distribution of drug samples to practitioners licensed or authorized to prescribe such drugs or to pharmacies of hospitals or other health care entities at the request of a licensed or authorized practitioner; (4) to require licensed or authorized practitioners to request prescription drug samples in writing; (5) to mandate storage, handling, and recordkeeping requirements for prescription drug samples; (6) to prohibit, with certain exceptions, the sale, purchase, or trade of, or the offer to sell, purchase, or trade, prescription drugs that were purchased by hospitals or other health care entities, or which were donated or supplied at a reduced price to a charitable organization; and (7) to require unauthorized wholesale distributors to provide, prior to the wholesale distribution of a prescription drug to another wholesale distributor or retail pharmacy, a statement identifying each prior sale, purchase, or trade of the drug.

In the Federal Register of November 14, 2014 (79 FR 68273), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

FDA estimates the burden of this collection of information as follows:

Table 1—Estimated Annual Reporting Burden 1

21 CFR sectionNumber of respondentsNumber of responses per respondentTotal annual respondentsAverage burden per responseTotal hours
203.11 Re-importation111.50 (30 minutes)1
203.30(a)(1) and (b) Drug sample requests61,96112743,532.06 (4 minutes)44,612
203.30(a)(3), (a)(4), (c) Drug sample receipts61,96112743,532.06 (4 minutes)44,612
203.31(a)(1) and (b) Drug sample requests232,35513531,367,925.04 (2 minutes)1,254,717
203.31(a)(3), (a)(4), (c) Drug sample receipts232,35513531,367,925.03 (2 minutes)941,038
203.37(a) Falsification of records504200.25 (15 minutes)50
203.37(b) Loss or theft of samples50402,000.25 (15 minutes)500
203.37(c) Convictions11111
203.37(d) Contact person50150.08 (5 minutes)4
203.39(g) Reconciliation report11111
1 There are no capital costs or operating and maintenance costs associated with this collection of information.

Table 2—Estimated Annual Recordkeeping Burden 1

21 CFR sectionNumber of recordkeepersNumber of records per recordkeeperTotal annual recordsAverage burden per recordkeepingTotal hours
203.23(a) and (b) Returned drugs31,6765158,380.25 (15 minutes)39,595
203.23(c) Returned drugs documentation31,6765158,380.08 (5 minutes)12,670
203.30(a)(2) and 203.31(a)(2) Practitioner verification2,208100220,800.50 (30 minutes)110,400
203.31(d)(1) and (d)(2) Inventory record and reconciliation report2,20812,2084088,320
203.31(d)(4) Investigation of discrepancies and losses44214422410,608
203.31(e) Representatives lists2,20812,20812,208
203.34 Administrative systems90190403,600
203.37(a) Falsification of drug sample records50420061,200
203.37(b) Loss or theft of drug samples50402,000612,000
203.39(d) Destroyed or returned drug samples65165165
203.39(e) Donated drug samples3,22113,221.50 (30 minutes)1,611
203.39(f) Distribution of donated drug samples3,22113,221825,768
203.39(g) Drug samples donated to charitable institutions3,22113,221825,768
203.50(a) Drug origin statement12510012,500.17 (10 minutes)2,125
203.50(b) Drug origin statement retention12510012,500.50 (30 minutes)6,250
203.50(d) Authorized distributors of record691169121,382
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
Start Signature

Dated: February 23, 2015.

Leslie Kux,

Associate Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2015-04131 Filed 2-26-15; 8:45 am]